Accelerating Global Regenerative Medicine with Automated Cell Systems to Thailand

Leading the Industrialization of Regenerative Medicine through a Partnership with MEDEZE

Shibuya has officially delivered the world’s first "Automated Cell Culture System for Autologous Cell Banks," which performs stem cell culturing, expansion, and harvesting entirely without human intervention, to MEDEZE, a leading advanced medical enterprise in Thailand. Advancing from the system overview introduced in 2024, this milestone marks our entry into the stage of commercial application. By combining our expertise in sterility control and liquid handling technologies, Shibuya is positioned to capture growing global cell banking demand, driving the industrialization of regenerative medicine across Asia and international markets.

Maximizing Biosafety through a Completely Unmanned Cell Culture System

The core of this technology lies in the "Automated Cell Culture System," which maintains an uncompromised sterile environment. The architecture completely eliminates humans—the primary source of contamination in traditional cell manufacturing—from the active work area. Within the sealed, highly sterile environment of the "Cell Processing Unit," robotic systems automatically execute critical sequential processes, including media exchange, seeding onto cell scaffolds, and cell passages, reducing human error and contamination risks to the absolute minimum.

Furthermore, the system is equipped with Autonomous Mobile Robots ("AMR") alongside numerous isolated "Incubation Units" (cell storage chambers). To safely transport cell samples that are highly sensitive to physical shock and environmental fluctuations, the AMRs navigate smoothly using advanced control algorithms. The robots seamlessly bridge the gap between approximately 100 individual mini-incubators and the "Cell Processing Unit" to create an unmanned space. Eliminating human presence allows the system to maintain the hyper-stable thermal conditions optimal for delicate living cells, enabling consistent, high-quality cell manufacturing.

Revolutionizing Throughput via a Next-Generation Commercial Line Production Method

By transforming cell processing from conventional batch work into an efficient "Line Production Method"—where sequential tasks are fragmented and transferred seamlessly like a relay race—we have established a commercial large-scale manufacturing infrastructure. This configuration boasts an overwhelming processing capacity of up to 24 batches per day. Concerns regarding cross-contamination between individual patient samples are completely eliminated through precise management of differential pressure, airflow control, ventilation, and strict operational protocols across each dedicated workspace.

Delivering Comprehensive Engineering to Provide Turnkey Global Cell Solutions

Shibuya’s primary advantage extends beyond manufacturing and delivering cutting-edge machinery; we provide a comprehensive "Total Solution" encompassing facility validation, software integration, and operational compliance management. We have established a robust engineering framework capable of navigating strict international pharmaceutical and medical device regulations, making this successful delivery and operation at MEDEZE a global benchmark for the industry. As a next-generation infrastructure that maximizes client brand value, we are committed to delivering safe, high-quality therapies and healthy aging options to people worldwide.